Completed PHASE1 INTERVENTIONAL 4-arm NCT06831812

Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of AV-1959R in Healthy Participants

Sponsor: Arvax

Conditions Alzheimer Disease Alzheimer Disease (AD) Alzheimers Disease Prevention

Interventions AV-1959R (Abeta vaccine)

Updated 5 times since 2025 Last updated: Feb 17, 2026 Started: Jun 12, 2024 Primary completion: Dec 1, 2025 Completion: Dec 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06831812, this PHASE1 trial focuses on Alzheimer Disease and Alzheimer Disease (AD) and remains completed. Sponsored by Arvax, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE1
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
Apr 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE1
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE1

First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arvax
Nuravax, Inc.

Data source: Nuravax, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia